BR112017011982A2 - roedor, polipeptídeo pd-l1, célula ou tecido isolado de roedor, célula-tronco embrionária de roedor, embrião de roedor, e, métodos para produção de um roedor, para reduzir o crescimento do tumor em um roedor, para matar células tumorais em um roedor, para avaliar as propriedades farmacocinéticas de um fármaco e para avaliar a eficácia de um fármaco. - Google Patents

roedor, polipeptídeo pd-l1, célula ou tecido isolado de roedor, célula-tronco embrionária de roedor, embrião de roedor, e, métodos para produção de um roedor, para reduzir o crescimento do tumor em um roedor, para matar células tumorais em um roedor, para avaliar as propriedades farmacocinéticas de um fármaco e para avaliar a eficácia de um fármaco.

Info

Publication number
BR112017011982A2
BR112017011982A2 BR112017011982A BR112017011982A BR112017011982A2 BR 112017011982 A2 BR112017011982 A2 BR 112017011982A2 BR 112017011982 A BR112017011982 A BR 112017011982A BR 112017011982 A BR112017011982 A BR 112017011982A BR 112017011982 A2 BR112017011982 A2 BR 112017011982A2
Authority
BR
Brazil
Prior art keywords
rodent
drug
cell
methods
assess
Prior art date
Application number
BR112017011982A
Other languages
English (en)
Portuguese (pt)
Inventor
J Murphy Andrew
Burova Elena
Venus Lai Ka-Man
Tang Yajun
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of BR112017011982A2 publication Critical patent/BR112017011982A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Environmental Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112017011982A 2014-12-09 2015-12-09 roedor, polipeptídeo pd-l1, célula ou tecido isolado de roedor, célula-tronco embrionária de roedor, embrião de roedor, e, métodos para produção de um roedor, para reduzir o crescimento do tumor em um roedor, para matar células tumorais em um roedor, para avaliar as propriedades farmacocinéticas de um fármaco e para avaliar a eficácia de um fármaco. BR112017011982A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462089549P 2014-12-09 2014-12-09
US201562106525P 2015-01-22 2015-01-22
PCT/US2015/064626 WO2016094481A1 (en) 2014-12-09 2015-12-09 Non-human animals having a humanized cluster of differentiation 274 gene

Publications (1)

Publication Number Publication Date
BR112017011982A2 true BR112017011982A2 (pt) 2018-01-16

Family

ID=55024286

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017011982A BR112017011982A2 (pt) 2014-12-09 2015-12-09 roedor, polipeptídeo pd-l1, célula ou tecido isolado de roedor, célula-tronco embrionária de roedor, embrião de roedor, e, métodos para produção de um roedor, para reduzir o crescimento do tumor em um roedor, para matar células tumorais em um roedor, para avaliar as propriedades farmacocinéticas de um fármaco e para avaliar a eficácia de um fármaco.

Country Status (27)

Country Link
US (4) US9913461B2 (cg-RX-API-DMAC7.html)
EP (3) EP3230320B1 (cg-RX-API-DMAC7.html)
JP (3) JP2018500896A (cg-RX-API-DMAC7.html)
KR (2) KR102457921B1 (cg-RX-API-DMAC7.html)
CN (2) CN113412818B (cg-RX-API-DMAC7.html)
AU (3) AU2015360667B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017011982A2 (cg-RX-API-DMAC7.html)
CA (1) CA2968675C (cg-RX-API-DMAC7.html)
CY (1) CY1123723T1 (cg-RX-API-DMAC7.html)
DK (2) DK3808775T3 (cg-RX-API-DMAC7.html)
ES (2) ES2982515T3 (cg-RX-API-DMAC7.html)
FI (1) FI3808775T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20202034T1 (cg-RX-API-DMAC7.html)
HU (2) HUE067123T2 (cg-RX-API-DMAC7.html)
IL (3) IL282649B (cg-RX-API-DMAC7.html)
LT (2) LT3808775T (cg-RX-API-DMAC7.html)
MX (1) MX2017007636A (cg-RX-API-DMAC7.html)
NZ (2) NZ731954A (cg-RX-API-DMAC7.html)
PL (1) PL3808775T3 (cg-RX-API-DMAC7.html)
PT (2) PT3808775T (cg-RX-API-DMAC7.html)
RS (2) RS65664B1 (cg-RX-API-DMAC7.html)
RU (1) RU2711729C2 (cg-RX-API-DMAC7.html)
SG (2) SG10202100792XA (cg-RX-API-DMAC7.html)
SI (2) SI3230320T1 (cg-RX-API-DMAC7.html)
SM (2) SMT202400313T1 (cg-RX-API-DMAC7.html)
WO (1) WO2016094481A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201703263B (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE067123T2 (hu) * 2014-12-09 2024-10-28 Regeneron Pharma Humanizált differenciációs klaszter 274 génnel rendelkezõ nem humán állatok
JP6997708B2 (ja) 2015-11-20 2022-02-04 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化されたｌｙｍｐｈｏｃｙｔｅ－ａｃｔｉｖａｔｉｏｎ ｇｅｎｅ ３遺伝子を有する非ヒト動物
SG11201806176PA (en) 2016-02-04 2018-08-30 Regeneron Pharma Non-human animals having an engineered angptl8 gene
AU2017228293B2 (en) 2016-02-29 2023-05-25 Regeneron Pharmaceuticals, Inc. Rodents having a humanized Tmprss gene
US10912287B2 (en) 2016-06-28 2021-02-09 Biocytogen Pharmaceuticals (Beijing) Co., Ltd Genetically modified mice expressing humanized PD-1
WO2018041118A1 (en) 2016-08-31 2018-03-08 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric pd-l1
CN107815466B (zh) 2016-08-31 2020-03-13 百奥赛图江苏基因生物技术有限公司 人源化基因改造动物模型的制备方法及应用
WO2018041120A1 (en) 2016-08-31 2018-03-08 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric tigit
CN107815467B (zh) * 2016-08-31 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化基因改造动物模型的制备方法及应用
US10736976B2 (en) 2016-12-01 2020-08-11 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging
WO2019072241A1 (en) 2017-10-13 2019-04-18 Beijing Biocytogen Co., Ltd NON-HUMAN ANIMAL GENETICALLY MODIFIED WITH PD-1 HUMAN OR CHIMERIC
CN109666701B (zh) * 2017-10-13 2021-08-24 百奥赛图(北京)医药科技股份有限公司 一种pd-1基因修饰人源化动物模型的构建方法及其应用
IL274740B2 (en) 2017-11-30 2024-06-01 Regeneron Pharma Non-human animals comprising a humanized trkb locus
CN109913493B (zh) 2017-12-12 2021-03-16 百奥赛图江苏基因生物技术有限公司 人源化cd3基因改造动物模型的制备方法及应用
CA3093850A1 (en) 2018-03-26 2019-10-03 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents
FI3823443T3 (fi) 2018-07-16 2024-07-25 Regeneron Pharma Ditra-taudin jyrsijämallit ja niiden käyttö
CN110846321B (zh) * 2018-08-21 2021-11-19 中国科学院动物研究所 一种突变基因及其用于构建斑色鱼鳞癣小型猪模型的用途
US20210380978A1 (en) * 2018-10-15 2021-12-09 The Brigham And Women`S Hospital, Inc. The long non-coding RNA INCA1 and Homo sapiens heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1) as therapeutic targets for immunotherapy
CN109452229B (zh) * 2018-11-19 2021-10-22 百奥赛图(北京)医药科技股份有限公司 狗源化pd-1基因改造动物模型的制备方法及应用
CN109979539B (zh) * 2019-04-10 2020-10-02 电子科技大学 基因序列优化方法、装置及数据处理终端
US20240130340A1 (en) * 2021-02-19 2024-04-25 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric cd3 genes
CN112999368A (zh) * 2021-04-09 2021-06-22 广东药康生物科技有限公司 人源化模型进行药效评价方法的建立

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670356A (en) 1994-12-12 1997-09-23 Promega Corporation Modified luciferase
US6485964B1 (en) * 1995-03-20 2002-11-26 Arris Pharmaceutical Corporation Transgenic mammals lacking expression of erythropoietin or of erythropoietin receptor, transgenic mammals expressing chimeric erythropoietin receptors, constructs for producing the transgenic mammals and uses therefor
GB9517780D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
GB9517779D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
WO2002000730A2 (en) 2000-06-28 2002-01-03 Genetics Institute, Llc. Pd-l2 molecules: novel pd-1 ligands and uses therefor
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
AU2002258941A1 (en) 2001-04-20 2002-11-05 Mayo Foundation For Medical Education And Research Methods of enhancing cell responsiveness
DE10211088A1 (de) * 2002-03-13 2003-09-25 Ugur Sahin Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
ES2350687T3 (es) 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
DE60322426D1 (cg-RX-API-DMAC7.html) * 2002-12-16 2008-09-04 Genentech Inc
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
ES2587344T3 (es) 2003-12-24 2016-10-24 Novo Nordisk A/S Ratón transgénico que comprende un polinucleótido que codifica C5aR humano o humanizado
WO2005060739A1 (en) 2003-12-24 2005-07-07 G2 Inflammation Pty Ltd Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5ar
SI1810026T1 (en) 2004-10-06 2018-08-31 Mayo Foundation For Medical Education And Research B7-H1 and PD-1 in the treatment of renal cell carcinoma
EP1802193B1 (en) 2004-10-19 2014-04-30 Regeneron Pharmaceuticals, Inc. Method for generating a mouse homozygous for a genetic modification
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
EP1997887B1 (en) 2006-03-03 2013-09-04 Ono Pharmaceutical Co., Ltd. Multimer of extracellular domain of cell surface functional molecule
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
BRPI0920679A2 (pt) 2008-10-08 2022-05-17 Intrexon Corp Células construídas expressando múltiplos imunomoduladores e usos das mesmas
US20110314563A1 (en) * 2008-12-18 2011-12-22 Kingdon Craig R Antibody production
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
US8354389B2 (en) 2009-08-14 2013-01-15 Regeneron Pharmaceuticals, Inc. miRNA-regulated differentiation-dependent self-deleting cassette
MX2012002427A (es) * 2009-08-28 2012-08-03 Vlst Corp Anticuerpos anticina que se unen a quimiocinas cc multiples.
ES2700852T3 (es) 2009-10-06 2019-02-19 Regeneron Pharma Ratones modificados genéticamente e injerto
WO2011060357A2 (en) 2009-11-16 2011-05-19 The Ohio State University Engineered xenogeneic cells for repair of biological tissue
MX343747B (es) 2009-11-24 2016-11-22 Medimmune Ltd Agentes de union diana contra b7-h1.
RS57280B1 (sr) * 2009-12-21 2018-08-31 Regeneron Pharma Humanizovani fc gamma r miševi
EP2555778A4 (en) * 2010-04-06 2014-05-21 Alnylam Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR INHIBITING CD274 / PD-L1 GENE EXPRESSION
KR102256316B1 (ko) * 2011-02-15 2021-05-28 리제너론 파마슈티칼스 인코포레이티드 인간화된 ｍ－ｃｓｆ 마우스
ES2741649T3 (es) 2011-10-28 2020-02-11 Regeneron Pharma Ratones con complejo mayor de histocompatibilidad modificado genéticamente
CA2853731C (en) 2011-10-28 2021-05-18 Regeneron Pharmaceuticals, Inc. Humanized il-6 and il-6 receptor
CN104039133B (zh) 2011-10-28 2018-05-04 瑞泽恩制药公司 表达嵌合主要组织相容性复合物(mhc)ii类分子的基因修饰小鼠
WO2013078230A1 (en) 2011-11-23 2013-05-30 The Trustees Of The University Of Pennsylvania Use of pdl1 expressing cells to convert t cells into regulatory t cells
MX349096B (es) 2011-11-28 2017-07-11 Merck Patent Gmbh Anticuerpos anti-pd-l1 y sus usos.
EP2890715B1 (en) 2012-08-03 2020-12-16 Dana-Farber Cancer Institute, Inc. Single agent anti-pd-l1 and pd-l2 dual binding antibodies and methods of use
US20140047572A1 (en) * 2012-08-13 2014-02-13 University Of Rochester Thrombopoietin mimetics for the treatment of radiation or chemical induced bone marrow injury
PT3470432T (pt) * 2012-08-21 2021-12-14 Regeneron Pharma Métodos para tratamento ou prevenção da asma por meio de administração de um antagonista de il-4r
CN108782459B (zh) 2012-09-07 2021-11-05 再生元制药公司 经遗传修饰的非人动物及其使用方法
IL299887B2 (en) 2012-11-05 2024-09-01 Regeneron Pharma Genetically modified non-human animals and methods of use thereof
WO2014116846A2 (en) 2013-01-23 2014-07-31 Abbvie, Inc. Methods and compositions for modulating an immune response
KR102714111B1 (ko) * 2013-02-20 2024-10-11 리제너론 파아마슈티컬스, 인크. 사람화된 ｔ-세포 보조-수용체를 발현하는 마우스
EP2958990B1 (en) 2013-02-20 2019-10-16 Regeneron Pharmaceuticals, Inc. Genetic modification of rats
HRP20181866T1 (hr) * 2013-02-22 2019-01-25 Regeneron Pharmaceuticals, Inc. Miševi koji izražavaju humanizirane komplekse glavne histokompatibilnosti
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
KR20200136508A (ko) * 2013-04-16 2020-12-07 리제너론 파마슈티칼스 인코포레이티드 랫트 게놈의 표적화된 변형
CN103242448B (zh) * 2013-05-27 2015-01-14 郑州大学 一种全人源化抗pd-1单克隆抗体及其制备方法和应用
US20160122829A1 (en) 2013-06-06 2016-05-05 Dana-Farber Cancer Institute, Inc. Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Cancer Using PD-L1 Isoforms
KR102370419B1 (ko) 2013-09-23 2022-03-04 리제너론 파마슈티칼스 인코포레이티드 인간화된 신호-조절 단백질 유전자를 가지는 비-인간 동물
WO2015077071A1 (en) 2013-11-19 2015-05-28 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized b-cell activating factor gene
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
DK3129400T3 (da) 2014-04-08 2020-06-08 Regeneron Pharma Ikke-humane dyr med humaniserede Fc-gamma-receptorer
NO2785538T3 (cg-RX-API-DMAC7.html) 2014-05-07 2018-08-04
PT3482629T (pt) 2014-05-19 2021-02-18 Univ Yale Animais não humanos geneticamente modificados que expressam epo humana
BR112016029650A2 (pt) * 2014-06-19 2017-10-24 Regeneron Pharma roedor, polipeptídeo pd-1, célula isolada ou tecido de roedor, célula-tronco embrionária de roedor, métodos de produzir um roedor, de reduzir o crescimento de tumor em um roedor, de matar células tumorais em um roedor e de avaliar as propriedades farmacocinéticas de uma droga que direciona pd-1 humano, e, modelo de tumor de roedor?
PL3689140T3 (pl) 2014-11-24 2022-09-05 Regeneron Pharmaceuticals, Inc. Zwierzęta inne niż ludzie eksprymujące humanizowany kompleks CD3
IL286403B2 (en) 2014-12-05 2023-10-01 Regeneron Pharma Non-human animals possess a humanized CLUSTER OF DIFFERENTIATION 47 gene
HUE067123T2 (hu) * 2014-12-09 2024-10-28 Regeneron Pharma Humanizált differenciációs klaszter 274 génnel rendelkezõ nem humán állatok
JP6997708B2 (ja) 2015-11-20 2022-02-04 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化されたｌｙｍｐｈｏｃｙｔｅ－ａｃｔｉｖａｔｉｏｎ ｇｅｎｅ ３遺伝子を有する非ヒト動物
WO2018041118A1 (en) 2016-08-31 2018-03-08 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric pd-l1

Also Published As

Publication number Publication date
US9913461B2 (en) 2018-03-13
CA2968675A1 (en) 2016-06-16
CN107257624B (zh) 2021-07-13
ZA201703263B (en) 2023-02-22
EP3230320B1 (en) 2020-10-07
IL282649A (en) 2021-06-30
FI3808775T3 (fi) 2024-07-02
US20180160663A1 (en) 2018-06-14
RU2017123754A3 (cg-RX-API-DMAC7.html) 2019-06-24
US20160157469A1 (en) 2016-06-09
JP7488861B2 (ja) 2024-05-22
JP2022184973A (ja) 2022-12-13
PL3808775T3 (pl) 2024-08-19
HRP20202034T1 (hr) 2021-02-19
US10881086B2 (en) 2021-01-05
RS65664B1 (sr) 2024-07-31
IL252695A0 (en) 2017-08-31
ES2841353T3 (es) 2021-07-08
IL282649B (en) 2022-07-01
CY1123723T1 (el) 2022-03-24
CN107257624A (zh) 2017-10-17
KR102457921B1 (ko) 2022-10-25
DK3808775T3 (da) 2024-07-01
SI3808775T1 (sl) 2024-08-30
WO2016094481A1 (en) 2016-06-16
LT3808775T (lt) 2024-07-10
IL252695B (en) 2020-07-30
EP3230320A1 (en) 2017-10-18
AU2021286369A1 (en) 2022-01-20
HUE067123T2 (hu) 2024-10-28
AU2021286369B2 (en) 2025-03-27
CA2968675C (en) 2023-10-17
CN113412818A (zh) 2021-09-21
HRP20240855T1 (hr) 2024-10-11
KR102316842B1 (ko) 2021-10-25
SG10202100792XA (en) 2021-03-30
AU2015360667B2 (en) 2021-09-23
EP4399969A3 (en) 2024-10-30
CN113412818B (zh) 2022-11-04
US20240389563A1 (en) 2024-11-28
IL275864B (en) 2021-05-31
JP2021003130A (ja) 2021-01-14
PT3230320T (pt) 2021-01-08
RU2711729C2 (ru) 2020-01-21
NZ770783A (en) 2024-11-29
JP2018500896A (ja) 2018-01-18
KR20210130251A (ko) 2021-10-29
AU2015360667A1 (en) 2017-06-08
EP3808775A1 (en) 2021-04-21
ES2982515T3 (es) 2024-10-16
SMT202100148T1 (it) 2021-05-07
SG11201703931QA (en) 2017-06-29
AU2025204751A1 (en) 2025-07-17
RS61218B1 (sr) 2021-01-29
MX2017007636A (es) 2018-03-28
LT3230320T (lt) 2021-01-11
NZ731954A (en) 2024-11-29
US20210105983A1 (en) 2021-04-15
DK3230320T3 (da) 2021-01-11
KR20170101910A (ko) 2017-09-06
RU2017123754A (ru) 2019-01-10
IL275864A (en) 2020-08-31
PT3808775T (pt) 2024-07-09
JP7145920B2 (ja) 2022-10-03
US12089575B2 (en) 2024-09-17
SI3230320T1 (sl) 2021-02-26
SMT202400313T1 (it) 2024-09-16
EP3808775B1 (en) 2024-04-17
HUE052606T2 (hu) 2021-05-28
EP4399969A2 (en) 2024-07-17

Similar Documents

Publication Publication Date Title
BR112017011982A2 (pt) roedor, polipeptídeo pd-l1, célula ou tecido isolado de roedor, célula-tronco embrionária de roedor, embrião de roedor, e, métodos para produção de um roedor, para reduzir o crescimento do tumor em um roedor, para matar células tumorais em um roedor, para avaliar as propriedades farmacocinéticas de um fármaco e para avaliar a eficácia de um fármaco.
BR112016029650A2 (pt) roedor, polipeptídeo pd-1, célula isolada ou tecido de roedor, célula-tronco embrionária de roedor, métodos de produzir um roedor, de reduzir o crescimento de tumor em um roedor, de matar células tumorais em um roedor e de avaliar as propriedades farmacocinéticas de uma droga que direciona pd-1 humano, e, modelo de tumor de roedor?
BR112018010158A2 (pt) roedor, polipeptídeo lag-3 humanizado, célula ou tecido, célula-tronco embrionária e embrião de roedor, métodos para produzir um roedor, para avaliar a eficácia antitumoral e as propriedades farmacocinéticas de uma droga
BR112017010490A2 (pt) roedor, polipeptídeo cd47, célula ou tecido de roedor isolado, célula-tronco emprionária de roedor, embrião de roedor, e, métodos de produzir um roedor, de fornecimento de um roedor, de enxerto de células humanas em um roedor, de avaliação de eficácia terapêutica de uma droga direcionada a células humanas e de avaliar as propriedades farmacocinéticas, de avaliar a toxicidade específica e inespecífica de uma droga direcionada ao cd47 humano.
CL2020000345A1 (es) Mezclas agrícolas.
EP4317445A3 (en) Humanized c5 and c3 animals
BR112016011003A2 (pt) animal roedor geneticamente modificado, célula tronco embrionária de camundongo, embrião de camundongo, e, métodos para fabricar um animal roedor e para enxertar células humanas em um camundongo
EA201991255A1 (ru) Регулируемая транскрипция
BR112016025745A2 (pt) roedor, camundongo, métodos para produção de um roedor e de um camundongo e para triagem de antagonista
BR112015029904A2 (pt) animais geneticamente estéreis
HRP20251062T1 (hr) Neljudske životinje koje imaju gen humaniziranog proteina za reguliranje signala
Scerbo et al. Ventx factors function as Nanog-like guardians of developmental potential in Xenopus
MX2019012311A (es) Metodos y composiciones para modificaciones geneticas dirigidas y metodos de uso.
BR112016011004A2 (pt) animal roedor geneticamente modificado, célula tronco embrionária de roedor, embrião de roedor, e, métodos para fabricar um animal roedor e para enxertar células humanas em um camundongo
EP3468356A4 (en) GENETICALLY MODIFIED CELLS, TISSUES AND ORGANS FOR THE TREATMENT OF A DISEASE
EA202090931A3 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
MX380555B (es) Combinación de anticuerpos anti-gen 3 de la activación de linfocito (lag-3) y anticuerpos anti-muerte celular programada 1 (pd-1) para usarse en el tratamiento de tumores.
BR112016006261A2 (pt) camundongo, célula ou tecido de camundongo isolado, e, métodos para produzir um camundongo, para enxertar células humanas em um camundongo e para avaliar a eficácia terapêutica de uma droga que alveja células humanas
AR100216A1 (es) Edición de genes multiplexados
BR112016024565A2 (pt) composições e métodos de tratar hemoglobinopatias
BR112016002385A2 (pt) animal não humano, célula, tecido ou embrião, vetor de alvejamento, constructo de vetor de alvejamento, e, métodos para produzir um animal não humano e para modificar um lócus de incrna em uma célula pluripotente
BR112016026245A2 (pt) ?roedor, e, métodos para fazer um roedor humanizado, para fazer um camundongo com dpp4 humanizado, para fazer um roedor transgênico humanizado e para determinar a eficácia terapêutica in vivo de um antagonista da dpp4 específica para humanos no roedor?
EP4069821A4 (en) SYSTEM FOR PRODUCING CULTURED MEAT, TISSUES AND RELATED PRODUCTS FROM CELLS
BR112018001232A2 (pt) pd-l1 que expressa células-tronco hematopoéticas e usos
O’Rourke et al. Biology and diseases of amphibians

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]